SNY Sanofi

   By William Horobin 
 

PARIS--France's Sanofi SA (SAN.FR) said Tuesday the Food and Drug Administration has approved tuberculosis drug Priftin.

Priftin is a tablet for the treatment of latent tuberculosis infection in patients over two years who are at high risk of progressing to tuberculosis disease.

At present, Priftin is only available in the U.S., but Sanofi is looking into regulatory approvals in other countries, the company said.

-Write to William Horobin at william.horobin@wsj.com